TerminatedPhase 1NCT05238207

A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers

Studying Hereditary Hemochromatosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bond Biosciences
Principal Investigator: Curtis Scribner, MD, LCSW
Sponsor GmbH
Intervention: BBI-001(drug)
Enrollment: 24 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2022 – 2023

Study locations (1)

Nucleus Networks, Melbourne, Victoria, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05238207 on ClinicalTrials.gov

← Back to all trials